<DOC>
	<DOC>NCT02571712</DOC>
	<brief_summary>A study to evaluate the long-term safety of GANFORT® (bimatoprost 0.03% plus timolol 0.5%) in Chinese patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to topical beta-blocker or prostaglandin analogues.</brief_summary>
	<brief_title>Safety of GANFORT® Ophthalmic Solution in Chinese Patients With Open-angle Glaucoma or Ocular Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma, Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Cloprostenol</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<mesh_term>Bimatoprost</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Diagnosis of openangle glaucoma or ocular hypertension that is insufficiently responsive to topical betablockers or prostaglandin analogues in one or both eyes Is willing to stop other intraocular pressure (IOP)lowering medications and switch to GANFORT® as a single agent in affected eye(s). Reactive airway disease including bronchial asthma or a history of bronchial asthma or severe chronic obstructive pulmonary disease Sinus bradycardia, sick sinus syndrome, sinoatrial block, second or third degree atrioventricular block, not controlled with pacemaker. Overt cardiac failure, cardiogenic shock.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>